Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
about
GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteinsLRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site statusLRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowthARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2Insight into the mode of action of the LRRK2 Y1699C pathogenic mutantFunctional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamilyMutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodiesLRRK2 phosphorylates novel tau epitopes and promotes tauopathy14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localizationLRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular modelMitochondrial dysfunction and oxidative stress in Parkinson's diseaseThe IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signalingSignal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticityNeurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegenerationUnexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).Watching worms whither: modeling neurodegeneration in C. elegans.Disruption of LRRK2 does not cause specific loss of dopaminergic neurons in zebrafish.The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.LRRK2 function on actin and microtubule dynamics in Parkinson diseasePhosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson diseaseTranscriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity.Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations.Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localizationLRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.LRRK2 mutations and neurotoxicant susceptibilitySubstrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.LRRK2 in Parkinson's disease: function in cells and neurodegeneration.Genetic animal models of Parkinson's disease.Mechanisms of LRRK2-mediated neurodegeneration.New synaptic and molecular targets for neuroprotection in Parkinson's disease.Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesisLeucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.
P2860
Q21144926-18ACA408-5DBB-47F6-AEF2-5E641D04978FQ24300440-5CAA2A7F-0990-42B5-AEFB-F0CFBF1FEB88Q24300605-FAEF1431-660B-4D5E-B92F-5BB1F808D0F4Q24304347-36EE82B3-A843-48DB-8780-6FF6755C38DFQ24305448-2AB99675-35F8-41DA-9977-FB71CA39CEAEQ24306788-5591A874-2A4F-4428-9084-25754B956DA8Q24310218-B283A873-6468-450D-86E0-BB6AA3D263B4Q24318474-73B04BA9-1F60-44FD-B4D4-A6DA8F53AF09Q24338188-0C0211EE-51AB-47E9-9D33-9EA115063D3AQ24339094-2326CB79-17B2-41D3-9F1A-08CE3D91546CQ24656256-29647066-86D4-453A-9132-902FF3AB9A90Q27014051-9E59F4A5-3A0A-4530-8BE3-AB8E4A74C3C1Q28480459-EF732742-65E4-4625-A54D-36C6781172C3Q28748929-F0CBB68B-12F1-4544-A887-1093B1C9AE78Q30454029-B82F80F6-D686-40E1-AC21-1311DC1E7DDFQ30653185-DFBA4648-9A74-4098-9362-77DE5FEF55C2Q33757616-AF7DD354-91EB-454B-99DF-EA9104D8CEBCQ33837857-A9F86642-EC27-4716-AF9C-8BEB76A14C54Q33940936-DE8C5ABD-3879-49A6-83C2-5174C3FA9E41Q34236070-9D6DE112-25ED-4A49-ACF8-1E0F23B33908Q34280111-2AB98F38-2A83-4F05-ADC8-6A10A85FC194Q34452296-B65440E1-97D0-4733-894B-9E796C6480D4Q35100189-1273C41A-5938-402E-B526-AFA62F5F964AQ35605204-43B7F971-4401-4EC3-AD76-D530F928D45BQ36188579-002E68F3-747B-475E-9D5F-D2EE2BA44320Q36780383-3F3D28ED-4867-46F8-972C-B77B543A06C5Q36981223-BEF366B0-E7E0-4A11-ADC1-C1A826568360Q37071013-AF6B5FFA-33CD-4129-A248-6BA4EAE1F094Q37139305-1863495D-8F9B-4070-BA9B-CDC28C763EF7Q37249125-4BD4F6A1-F477-4838-8F91-C4F8DC1B0E0BQ37479332-A7B39C46-E0B1-496E-97F3-98E6D62977B3Q37608630-7F040E77-7866-42AD-B764-692BCA5AE69DQ37765030-AA7B57F5-A78A-4ABB-A795-F9B505B81222Q37996364-C4EE2237-2E8C-45BD-81B0-6BD6F4C3705AQ38038559-7493CD3B-0C2E-4370-ADE7-0B929AFD03B6Q38044449-C72357E1-8E14-4A09-8E0F-AE15AB743B4CQ38057769-72459625-CCC1-4907-81E9-EDC24414C5A1Q38218398-E316FFB0-2EF9-4E95-9785-90ADCCDD7928Q38219430-22AC6978-2CE5-4E02-8453-07D35F5110CAQ39137358-2BB3A168-22EE-4D8B-8ADB-664462C131C9
P2860
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
@en
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
@nl
type
label
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
@en
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
@nl
prefLabel
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
@en
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
@nl
P2860
P1476
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease
@en
P2093
Saskia Biskup
P2860
P304
P356
10.1016/J.BBADIS.2008.09.015
P407
P577
2008-10-10T00:00:00Z